Aclaris Therapeutics Inc

Financial Health of Aclaris Therapeutics Inc

Comparing to competitors in the Diagnostics & Research industry

Industry Rankings

Aclaris Therapeutics Inc
Buy, Hold or Sell?

Should you buy, hold or sell Aclaris Therapeutics Inc?

I guess you are interested in Aclaris Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Aclaris Therapeutics Inc

Let's start. I'm going to help you getting a better view of Aclaris Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Show more...

Company's Financial Health
A deep dive into the books. How are the numbers doing? Is Aclaris Therapeutics Inc even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
Market Valuation
Finally, you now have an insight of how Aclaris Therapeutics Inc is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Aclaris Therapeutics Inc. The closing price on 2022-12-02 was $16.64 per share. Is the company over- or underpriced?
Key Performance Indicators
A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.

Aclaris Therapeutics Inc Daily Candlestick Chart

Summary

Financial Health

Profitability Details

	Compared to previous year	Compared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.

Operating Efficiency Details

	Compared to previous year	Compared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.

Liquidity Details

	Compared to previous year	Compared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.

Solvency Details

	Compared to previous year	Compared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Aclaris Therapeutics Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Measures how much net profit Aclaris Therapeutics Inc earns for each $1 of revenue.

Above 10% is considered healthy but always compare Aclaris Therapeutics Inc to the Diagnostics & Research industry mean.
A Net Profit Margin of -104.9% means that $-1.05 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aclaris Therapeutics Inc:

The MRQ is -104.9%. The company is making a huge loss. -2
The TTM is -1,065.2%. The company is making a huge loss. -2

Trends

Current period		Compared to		+/-
MRQ	-104.9%	TTM	-1,065.2%	+960.3%
TTM	-1,065.2%	YOY	-1,180.5%	+115.3%
TTM	-1,065.2%	5Y	-1,461.3%	+396.0%
5Y	-1,461.3%	10Y	-937.8%	-523.5%

Compared to industry (Diagnostics & Research)

Period	Company	Industry (mean)	+/-
MRQ	-104.9%	-7.3%	-97.6%
TTM	-1,065.2%	-4.9%	-1,060.3%
YOY	-1,180.5%	0.5%	-1,181.0%
5Y	-1,461.3%	-5.8%	-1,455.5%
10Y	-937.8%	-3.4%	-934.4%

Measures how much net profit Aclaris Therapeutics Inc earns for each $1 of revenue.

Revenue is the amount of profit Aclaris Therapeutics Inc generates before taxes and all other costs. For example, when you buy a cup of coffee it will cost you $3. The company does not earn $3 in profit but also has to pay various costs and taxes to create that cup of coffee. Let's assume the cost of creating a cup of coffee is $1.5.

The $3 you pay for a cup of coffee is called revenue.
The $1.5 that’s left over when all costs to create that cup of coffee (including taxes) are deduced from the revenue is called net profit.

The net profit margin looks at how much net profit Aclaris Therapeutics Inc earns for each $1 in revenue.

How to use net profit margin

Higher profit margin is better (more profit).
Above 10% is considered healthy but always compare Aclaris Therapeutics Inc to the Diagnostics & Research industry mean.
Can be used to compare companies within the Diagnostics & Research industry.

You typically want a high profit margin. This means that for each $1 in sales, Aclaris Therapeutics Inc makes more profit. This shows the investor how efficiently Aclaris Therapeutics Inc is operating in general and compared to other companies in the same industry. Aclaris Therapeutics Inc operates in the Diagnostics & Research industry.

Why do investors use net profit margin in their analysis

It helps investors to determine the efficiency of Aclaris Therapeutics Inc. If profit margins remain low (compared to the Diagnostics & Research industry mean) and there are no improvements to make in production costs or other areas that might be a warning sign. If profit margins are high that means the company has low overhead costs and is efficiently using its resources to generate profit.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Net Profit Margin of Aclaris Therapeutics Inc is -1.05. This means that Aclaris Therapeutics Inc earned $-1.05 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Net Profit Margin of the Diagnostics & Research industry is -7.3%.
What is the trend?
The trend is important because it shows you how Aclaris Therapeutics Inc is performing over time. The most recent quarter might be important if Aclaris Therapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Aclaris Therapeutics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare Aclaris Therapeutics Inc with other companies in the same industry (Diagnostics & Research).
Net profit margin should rise over the years.
Can be influenced when Aclaris Therapeutics Inc sells assets (profit will increase while costs remain the same).
It won’t show what part of Aclaris Therapeutics Inc is doing great or needs improvement (it only looks at total revenue and total net income).

How to calculate net profit margin

Net profit margin = net income / total revenue * 100%

Real example of Aclaris Therapeutics Inc

You need the following data to determine net profit margin:

Income statement from the period you want to calculate (for example, MRQ or TTM).

Net income MRQ Aclaris Therapeutics Inc = -19,952
Total revenue MRQ Aclaris Therapeutics Inc = 19,018
$-19,952 / $19,018 = -1.05 or -104.9%

Higher is better

The higher the net profit margin, the more efficient the company is generating income. This helps investors to determine how the company is managing money. The net profit margin is an important indicator when diving into the financial health of a company. Overall, you want to see the net profit margin rising over the years. That means the company improved their production and made it more efficient (if possible).

You can use the net profit margin to compare companies within the same industry. If there are two companies where one is much bigger but the smaller one has a higher net profit margin, that means the smaller company is more efficiently using operational costs.

Important: Profit margins can be very different between industries. Companies with assembly lines or transports are much more prone to see shifting in prices for fuel, ingredients and maintenance compared to companies that only provide services. You should never compare net profit margin between different industries.

1.1.2. Return on Assets

Shows how efficient Aclaris Therapeutics Inc is using its assets to generate profit.

Above 5% is considered healthy but always compare Aclaris Therapeutics Inc to the Diagnostics & Research industry mean.
-7.5% Return on Assets means that Aclaris Therapeutics Inc generated $-0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aclaris Therapeutics Inc:

The MRQ is -7.5%. Using its assets, the company is very inefficient in making profit. -2
The TTM is -8.1%. Using its assets, the company is very inefficient in making profit. -2

Trends

Current period		Compared to		+/-
MRQ	-7.5%	TTM	-8.1%	+0.6%
TTM	-8.1%	YOY	-12.7%	+4.6%
TTM	-8.1%	5Y	-14.5%	+6.4%
5Y	-14.5%	10Y	-13.5%	-1.0%

Compared to industry (Diagnostics & Research)

Period	Company	Industry (mean)	+/-
MRQ	-7.5%	-0.5%	-7.0%
TTM	-8.1%	-0.4%	-7.7%
YOY	-12.7%	0.2%	-12.9%
5Y	-14.5%	-0.8%	-13.7%
10Y	-13.5%	-0.8%	-12.7%

Shows how efficient Aclaris Therapeutics Inc is using its assets to generate profit.

For a farm, a tractor is considered an asset. The tractor helps ploughing the land making it possible to plant and harvest crops. But the tractor might be old and needing maintenance all the time reducing its efficiency. Return on assets indicates how effectively the farm is using the tractor (and other assets that help the core business) to plough the land.

How to use return on assets

Higher is better.
Above 5% is considered healthy but always compare Aclaris Therapeutics Inc to the Diagnostics & Research industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on assets in their analysis

Shows the investor how effectively Aclaris Therapeutics Inc is using its resources to generate profit. If the return on assets (-7.5%) from Aclaris Therapeutics Inc are higher than the Diagnostics & Research mean (-0.5%) that means Aclaris Therapeutics Inc is using its resources better than their competitors. If not, that means their competitors are more efficient in using their resources to generate profit.

An investor should always look at:

What is the current return on assets?
The current most recent quarter (MRQ) Return on Assets of Aclaris Therapeutics Inc is -7.5%. This means the company generated $-0.07 for each $1 in assets.
How does it compare to the industry?
The mean MRQ Return on Assets of the Diagnostics & Research industry is -0.5%.
What is the trend?
The trend is important because it shows you how Aclaris Therapeutics Inc is performing over time. The most recent quarter might be important if Aclaris Therapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Aclaris Therapeutics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
If a company has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

How to calculate return on assets

Return on assets = net income / total assets * 100%

Real example Aclaris Therapeutics Inc

You need the following data to determine return on assets (ROA):

Income statement
Balance sheet

Net income MRQ (income statement) from Aclaris Therapeutics Inc = -19,952
Total assets MRQ (balance sheet) from Aclaris Therapeutics Inc = 267,632
-19,952 / 267,632 = -0.07 or -7.5%

ROA is an important ratio as it will tell you how effectively Aclaris Therapeutics Inc is using its resources to generate profits. Example:

Bob and Kristin both sell ice cream in the summer. They both have an ice cream truck. The truck Bob owes cost him $20.000 and the truck Kristin owes cost her $1500. Over the summer, Bob earned $2000 and Kristin earned $200. To calculate the return on assets:

Bob: $2000 / $20.000 * 100% = 10%
Kristin: $200 / $1500 * 100% = 13.3%

This tells you Bob’s company is more valuable but Kristin's company is more efficient. Be aware that total assets can change over time. A transportation business will buy and sell trucks or planes all the time. Before using return on assets as a guideline, you have to know what the exact assets are. For a company that has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

1.1.3. Return on Equity

Shows how efficient Aclaris Therapeutics Inc is using its investors money to generate profit.

Above 15%-20% is considered healthy but always compare Aclaris Therapeutics Inc to the Diagnostics & Research industry mean.
-9.1% Return on Equity means Aclaris Therapeutics Inc generated $-0.09 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aclaris Therapeutics Inc:

The MRQ is -9.1%. Using its investors money, the company is very inefficient in making profit. -2
The TTM is -9.9%. Using its investors money, the company is very inefficient in making profit. -2

Trends

Current period		Compared to		+/-
MRQ	-9.1%	TTM	-9.9%	+0.9%
TTM	-9.9%	YOY	-19.5%	+9.6%
TTM	-9.9%	5Y	-21.3%	+11.4%
5Y	-21.3%	10Y	-16.7%	-4.6%

Compared to industry (Diagnostics & Research)

Period	Company	Industry (mean)	+/-
MRQ	-9.1%	0.7%	-9.8%
TTM	-9.9%	0.3%	-10.2%
YOY	-19.5%	0.6%	-20.1%
5Y	-21.3%	-1.3%	-20.0%
10Y	-16.7%	-1.8%	-14.9%

Shows how efficient Aclaris Therapeutics Inc is using its investors money to generate profit.

A publicly traded company (any company that issues shares to the public) is owned by its shareholders. Return on equity calculates the amount of profit for every $1 the shareholders invested.

How to use return on equity

Higher is better.
Above 15%-20% is considered healthy but always compare Aclaris Therapeutics Inc to the Diagnostics & Research industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on equity in their analysis

To find out the owners/management's attitude toward their company. You typically want the owners/management to invest in the company and focus on generating profit. If not enough profit is generated (compared to the Diagnostics & Research industry mean), the company might not be investing their money efficiently.

The three steps every investor should look at:

What is the current return on equity?
The current most recent quarter (MRQ) Return on Equity of Aclaris Therapeutics Inc is -9.1%. This means Aclaris Therapeutics Inc generated $-0.09 for each $1 the owners (shareholders) invested.
How does it compare to the industry?
The mean MRQ Return on Equity of the Diagnostics & Research industry is 0.7%.
What is the trend?
The trend is important because it shows you how Aclaris Therapeutics Inc is performing over time. The most recent quarter might be important if Aclaris Therapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Aclaris Therapeutics Inc up to 10 years back (depending if Aclaris Therapeutics Inc existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Does not include intangible assets (non physical assets like licences, computer software, etc.).
Stockholders equity and shareholders equity refer to the same thing.
Liabilities should not be more than three times return on equity.

How to calculate return on equity

Return on equity = net profit / shareholders equity * 100%

Real example of Aclaris Therapeutics Inc

You need the following data to determine ROE:

Income statement
Balance sheet
Net profit MRQ (income statement) Aclaris Therapeutics Inc = -19,952
Shareholders equity (balance sheet) MRQ Aclaris Therapeutics Inc = 219,838
-19,952 / 219,838 = -0.09 or -9.1%

A negative shareholder equity is a warning sign. It means the company has more liabilities than assets. It might also mean that the owners did not invest enough money or they are taking money out of the business.

1.2. Operating Efficiency of Aclaris Therapeutics Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Measures how efficient Aclaris Therapeutics Inc is operating .

Measures how much profit Aclaris Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
Above 15% is considered healthy but always compare Aclaris Therapeutics Inc to the Diagnostics & Research industry mean.
An Operating Margin of -109.8% means the company generated $-1.10 for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aclaris Therapeutics Inc:

The MRQ is -109.8%. The company is operating very inefficient. -2
The TTM is -1,066.5%. The company is operating very inefficient. -2

Trends

Current period		Compared to		+/-
MRQ	-109.8%	TTM	-1,066.5%	+956.7%
TTM	-1,066.5%	YOY	-1,183.4%	+117.0%
TTM	-1,066.5%	5Y	-1,471.2%	+404.8%
5Y	-1,471.2%	10Y	-943.7%	-527.6%

Compared to industry (Diagnostics & Research)

Period	Company	Industry (mean)	+/-
MRQ	-109.8%	0.3%	-110.1%
TTM	-1,066.5%	-1.8%	-1,064.7%
YOY	-1,183.4%	1.1%	-1,184.5%
5Y	-1,471.2%	-2.5%	-1,468.7%
10Y	-943.7%	-1.6%	-942.1%

Measures how efficient Aclaris Therapeutics Inc is operating .

The more effecient a company creates products or provides services, the more profit it generates.

How to use operating margin

Higher is better
Above 15% is considered healthy but always compare Aclaris Therapeutics Inc to the Diagnostics & Research industry mean.
Can be very different between industries
Can be used to compare companies

Why do investors use operating margin in their analysis

To determine how much profit Aclaris Therapeutics Inc is making from it’s core business.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Operating Margin of Aclaris Therapeutics Inc is -109.8%. This means that Aclaris Therapeutics Inc earned $-1.10 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Margin of the Diagnostics & Research industry is 0.3%.
What is the trend?
The trend is important because it shows you how Aclaris Therapeutics Inc is performing over time. The most recent quarter might be important if Aclaris Therapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Aclaris Therapeutics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Can be calculated in different ways

How to calculate operating margin

Operating margin = operating earnings / total revenue

Real example of Aclaris Therapeutics Inc

You need the following data to determine operating margin:

Income statement
Operating earnings MRQ Aclaris Therapeutics Inc = -20,874
Total revenue MRQ Aclaris Therapeutics Inc = 19,018
$-20,874 / $19,018 = -1.10 or -109.8%

Operating margin is used to calculate how much profit a company makes after variable costs of production but before paying interest and taxes. Some variable costs examples are wages, raw materials, packaging, and transaction fees. The amount of variable costs is different for each company and industry. In general, a higher operating margin is better as this implicates that a company is running efficiently.

For investors, a higher operating margin is a good sign. Although you should always look at operating margin in the long term. If operating margin is fluctuating over the years this might be a sign that things are not running efficiently enough. It’s a way to check how much profit a company is making from its core business.

Operation earnings can be calculated in multiple ways:

Operation earnings = EBIT - non operating income + non operating expense
Operation earnings = Gross profit - operating expense - depreciation and amortisation
Operation earnings = Total revenue - COGS (costs of goods sold) - indirect costs

1.2.2. Operating Ratio

Measures how efficient Aclaris Therapeutics Inc is keeping operating costs low.

Below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
An Operation Ratio of 2.10 means that the operating costs are $2.10 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Aclaris Therapeutics Inc:

The MRQ is 2.098. The company is inefficient in keeping operating costs low. -1
The TTM is 12.172. The company is inefficient in keeping operating costs low. -1

Trends

Current period		Compared to		+/-
MRQ	2.098	TTM	12.172	-10.074
TTM	12.172	YOY	9.579	+2.592
TTM	12.172	5Y	13.370	-1.199
5Y	13.370	10Y	8.701	+4.670

Compared to industry (Diagnostics & Research)

Period	Company	Industry (mean)	+/-
MRQ	2.098	1.329	+0.769
TTM	12.172	1.234	+10.938
YOY	9.579	1.234	+8.345
5Y	13.370	1.103	+12.267
10Y	8.701	1.031	+7.670

Measures how efficient Aclaris Therapeutics Inc is keeping operating costs low.

If the operating ratio is below 1 that means the company is making money. The lower the operating ratio, the more efficient the company.

How to use operating ratio

Lower is better.
Below 1 is considered healthy but always compare Aclaris Therapeutics Inc to the Diagnostics & Research industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use operating ratio in their analysis

Shows if costs of creating products and or services is increasing or decreasing. The lower the operating ratio, the more efficient the company is creating products and services.

The three steps every investor should look at:

What is the current Operatin ratio?
The current most recent quarter (MRQ) Operating Ratio of Aclaris Therapeutics Inc is 209.8%. This means that Aclaris Therapeutics Inc earned $2.10 for each $1 in net sales in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Ratio of the Diagnostics & Research industry is 1.33.
What is the trend?
The trend is important because it shows you how Aclaris Therapeutics Inc is performing over time. The most recent quarter might be important if Aclaris Therapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Aclaris Therapeutics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
You need COGS to calculate operating ratio which is not always shown in the income statement.
Does not consider debt.

How to calculate operating ratio

Operating ratio = Operating expenses + COGS \ Net sales

Real life example Aclaris Therapeutics Inc

You need the following data to determine operating ratio:

Income statement

COGS is not always specified on the income statement. If so you can use the following calculation:

(cost of revenue + total operating expenses) \ total revenue
(923 +38,969) \ 19,018 = 2.10

The operating ratio measures the efficiency of a company at keeping low costs while generating profits from sales. It compares the total operating expenses to the net amount of sales. The total operating expenses exists of:

COGS (materials, labour, rent of facility, repairs)
Operating expenses (legal fees, marketing, wages, rent, maintenance/repairs)

Operating expenses are all the costs the company makes that are not directly tied to the production of the service or product. Where COGS are costs that are directly tied to the production of a product or service.

Do note that COGS is not always available in the income statement. Some companies include COGS in the operating expenses while others list COGS separately. To make it even more confusing, COGS is also known as “costs of sales” and costs of sales is the same as costs of revenue.

The operating ratio tells you how efficient the company is creating its products or services while keeping prices low. In this case, a lower ratio is better. Higher or rising operating ratios might tell you that costs are rising while sales are not improving or staying the same.

1.3. Liquidity of Aclaris Therapeutics Inc.

1.3. Liquidity

1.3.1. Current Ratio

Measures if Aclaris Therapeutics Inc is able to pay off Short-term Debt.

Above 1.5 is considered healthy (always compare to Diagnostics & Research industry mean).
A Current Ratio of 12.54 means the company has $12.54 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Aclaris Therapeutics Inc:

The MRQ is 12.535. The company is very able to pay all its short-term debts. +2
The TTM is 12.220. The company is very able to pay all its short-term debts. +2

Trends

Current period		Compared to		+/-
MRQ	12.535	TTM	12.220	+0.315
TTM	12.220	YOY	10.212	+2.008
TTM	12.220	5Y	8.426	+3.794
5Y	8.426	10Y	12.277	-3.851

Compared to industry (Diagnostics & Research)

Period	Company	Industry (mean)	+/-
MRQ	12.535	2.412	+10.123
TTM	12.220	2.617	+9.603
YOY	10.212	2.767	+7.445
5Y	8.426	2.626	+5.800
10Y	12.277	2.837	+9.440

Measures if Aclaris Therapeutics Inc is able to pay off Short-term Debt.

How to use current ratio

Higher is better
Above 1.5 is considered healthy (always compare to Diagnostics & Research industry mean).
Can be very different between industries
Can be used to compare companies

Why do investors use current ratio in their analysis

Shows if the company can pay of short term debts if needed. A company that can't pay off it's short term debts might get in trouble if they have to pay off their short term debts for whatever reason. For example, markets can change due to global events like covid-19 or the war in Ukraine versus Russia. Because debts are always taken based on future income, it might become troublesome for Aclaris Therapeutics Inc if something happens in the market that will cause sales to plummet.

The three steps every investor should look at:

What is the current current Ratio?
The current most recent quarter (MRQ) Current Ratio of Aclaris Therapeutics Inc is 12.54. This means Aclaris Therapeutics Inc has $12.54 in assets for each $1 in short-term debts.
How does it compare to the industry?
The mean MRQ Current Ratio of the Diagnostics & Research industry is 2.41.
What is the trend?
The trend is important because it shows you how Aclaris Therapeutics Inc is performing over time. The most recent quarter might be important if Aclaris Therapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Aclaris Therapeutics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Might be deluded.
Not all assets can always be quickly sold.
Can be manipulated by increasing or decreasing the assets and/or liabilities.

How to calculate current ratio

Current ratio = current assets \ current liabilities

Real life example Aclaris Therapeutics Inc

You need the following data to determine operating ratio:

Balance sheet
Current ratio = current assets \ current liabilities
248,062 \ 19,789) = 12.54

The current ratio measures if Aclaris Therapeutics Inc is able to pay short-term debts (obligations). Short term in this context means all debt obligations that are about to expire within one year. The current ratio incorporates current liabilities and current assets. Current assets are all the assets a company has that are expected to be consumed or sold within standard business operations. You can find the current assets in the balance sheet. They consist of:

Inventory
Accounts receivable
Marketable securities
Prepaid expenses
Cash
Cash equivalents
liquid assets

The current liabilities are short term obligations that are due within one year. These consist of:

Short term debts
Dividends
Income taxes
Short-term debts
Accounts payable
Interest payments

The result shows an investor if Aclaris Therapeutics Inc is able to pay all its short-term debts if they were due all at once. When the result of the above formula is below 1, then Aclaris Therapeutics Inc does not have enough capital after selling all its assets to pay all short-term debts. If the ratio drops far below 1 that might indicate Aclaris Therapeutics Inc is or will be in financial trouble anytime soon.

Although this gives an investor some clues, the current ratio may also be deluded. Because owning assets does not mean the company can easily sell them. Also, Accounts receivable may be quite old (they will probably never pay) which deludes the current ratio. As with all ratios, you should only compare them between the same industries and companies.

1.3.2. Quick Ratio

Measures if Aclaris Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

Above 1 is considered healthy but always compare Aclaris Therapeutics Inc to the Diagnostics & Research industry mean.
A Quick Ratio of 21.99 means the company can pay off $21.99 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aclaris Therapeutics Inc:

The MRQ is 21.985. The company is very able to pay all its short-term debts with the most liquid assets. +2
The TTM is 19.048. The company is very able to pay all its short-term debts with the most liquid assets. +2

Trends

Current period		Compared to		+/-
MRQ	21.985	TTM	19.048	+2.937
TTM	19.048	YOY	15.977	+3.071
TTM	19.048	5Y	13.317	+5.731
5Y	13.317	10Y	20.515	-7.198

Compared to industry (Diagnostics & Research)

Period	Company	Industry (mean)	+/-
MRQ	21.985	1.321	+20.664
TTM	19.048	1.454	+17.594
YOY	15.977	1.515	+14.462
5Y	13.317	1.553	+11.764
10Y	20.515	1.530	+18.985

Measures if Aclaris Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

How to use quick ratio

Higher is better.
Above 1 is considered healthy but always compare Aclaris Therapeutics Inc to the Diagnostics & Research industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use quick ratio in their analysis

Shows how fast Aclaris Therapeutics Inc can pay off its short term debts. This shows if Aclaris Therapeutics Inc can survive emergencies due to market changes or other reasons.

The three steps every investor should look at:

What is the current Quick Ratio?
The current most recent quarter (MRQ) quickRatio of Aclaris Therapeutics Inc is 21.99. This means that Aclaris Therapeutics Inc can pay off $21.99 for each $1 in debt (using most liquid assets).
How does it compare to the industry?
The mean MRQ Quick Ratio of the Diagnostics & Research industry is 1.32.
What is the trend?
The trend is important because it shows you how Aclaris Therapeutics Inc is performing over time. The most recent quarter might be important if Aclaris Therapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Aclaris Therapeutics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Incorporates only most liquid assets.

How to calculate quick ratio

Quick ratio = cash and equivalents + marketable securities + accounts receivable / current liabilities

Real life example Aclaris Therapeutics Inc

You need the following data to determine operating ratio:

Balance sheet
Quick ratio = cash and short-term investments + short-term investments + netReceivables / total current liabilities
MRQ quick ratio Aclaris Therapeutics Inc: (248,062 + 186,409 +597) / 19,789 = 21.99

The quick ratio measures the same thing as the current ratio, only it uses the most liquid assets a company has. Meaning, the assets that can be sold for cash the easiest and fastest.

As the quick ratio only incorporates the most liquid assets, you should also check the current ratio which also includes less liquid assets. But they may be harder to sell.

1.4. Solvency of Aclaris Therapeutics Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Measures how much % of Aclaris Therapeutics Inc assets are financed with debt.

Below 1 (100%) is considered healthy but always compare Aclaris Therapeutics Inc to Diagnostics & Research industry mean.
A Debt to Asset Ratio of 0.18 means that Aclaris Therapeutics Inc assets are financed with 17.9% credit (debt) and the remaining percentage (100% - 17.9%) is financed by its owners/shareholders.

Let's take a look of the Debt to Asset Ratio trends of Aclaris Therapeutics Inc:

The MRQ is 0.179. The company is very able to pay all its debts by selling its assets. +2
The TTM is 0.187. The company is very able to pay all its debts by selling its assets. +2

Trends

Current period		Compared to		+/-
MRQ	0.179	TTM	0.187	-0.009
TTM	0.187	YOY	0.285	-0.097
TTM	0.187	5Y	0.262	-0.074
5Y	0.262	10Y	0.355	-0.093

Compared to industry (Diagnostics & Research)

Period	Company	Industry (mean)	+/-
MRQ	0.179	0.404	-0.225
TTM	0.187	0.404	-0.217
YOY	0.285	0.433	-0.148
5Y	0.262	0.453	-0.191
10Y	0.355	0.442	-0.087

Measures how much % of Aclaris Therapeutics Inc assets are financed with debt.

When there are more debts than assets, that means creditors have a larger stake Aclaris Therapeutics Inc than its shareholders.

How to use debt to asset ratio

Lower is better.
below 1 (100%) is considered healthy but always compare Aclaris Therapeutics Inc to Diagnostics & Research industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to asset ratio in their analysis

It shows how much debt the company used to finance its assets. If a company is almost entirely financed with debt that means the company might get into serious trouble when emergencies arise like a raise in interest.

The three steps every investor should look at:

What is the current debt to asset ratio?
The current most recent quarter (MRQ) Debt to Asset Ratio of Aclaris Therapeutics Inc is 0.18. This means means that Aclaris Therapeutics Inc is financed with 17.9% credit and the remaining percentage is financed by it's owners (shareholders).
How does it compare to the industry?
The mean MRQ Current Ratio of the Diagnostics & Research industry is 241.2%.
What is the trend?
The trend is important because it shows you how Aclaris Therapeutics Inc is performing over time. The most recent quarter might be important if Aclaris Therapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Aclaris Therapeutics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Some companies can have higher debt to assets ratio's (for example, banks).
Debt to asset ratio should improve over the years.
If the debt to asset ratio is above 1, look at the industry mean and find out why Aclaris Therapeutics Inc has so much debt.

How to calculate debt to asset ratio

Debt to asset ratio = total debt \ total assets

Real life example Aclaris Therapeutics Inc

You need the following data to determine debt to asset ratio:

Balance sheet
Debt to asset ratio = total debt \ total assets
47,794 \ 267,632 = 17.9% or 0.18.

The debt to total assets ratio shows if the company is owned by creditors or shareholders. Or in other words, the total debt in relation to the total amount of assets. It shows how much debt the company used to finance its assets.

1.4.2. Debt to Equity Ratio

Measures if Aclaris Therapeutics Inc is able to pay off its debts by using shareholders equity.

Below 2 is considered healthy but always compare Aclaris Therapeutics Inc to the Diagnostics & Research industry mean.
A Debt to Equity ratio of 21.7% means that company has $0.22 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aclaris Therapeutics Inc:

The MRQ is 0.217. The company is very able to pay all its debts with equity. +2
The TTM is 0.232. The company is very able to pay all its debts with equity. +2

Trends

Current period		Compared to		+/-
MRQ	0.217	TTM	0.232	-0.014
TTM	0.232	YOY	0.441	-0.210
TTM	0.232	5Y	0.396	-0.165
5Y	0.396	10Y	0.331	+0.065

Compared to industry (Diagnostics & Research)

Period	Company	Industry (mean)	+/-
MRQ	0.217	0.598	-0.381
TTM	0.232	0.620	-0.388
YOY	0.441	0.672	-0.231
5Y	0.396	0.753	-0.357
10Y	0.331	0.741	-0.410

Measures if Aclaris Therapeutics Inc is able to pay off its debts by using shareholders equity.

How to use debt to equity ratio

Lower is better.
Below 2 is considered healthy (always use industry average).
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to shareholders equity ratio in their analysis

It shows how much debt the company uses to finance their operations. Shareholders equity is whats left over when you subtract total liabilities from total assets. It's another way to meassure how much of Aclaris Therapeutics Inc is financed with debt or own resources.

The three steps every investor should look at:

What is the current debt to equity ratio?
The current most recent quarter (MRQ) quickRatio of Aclaris Therapeutics Inc is 0.22. This means that Aclaris Therapeutics Inc can pay off $0.22 for each $1 in debt.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Diagnostics & Research industry is 0.60.
What is the trend?
The trend is important because it shows you how Aclaris Therapeutics Inc is performing over time. The most recent quarter might be important if Aclaris Therapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Aclaris Therapeutics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Not all debt is equally risky (for example, short term risk is less risky).

How to calculate debt to equity ratio

Debt to equity ratio = total debt \ shareholders equity.

Real life example Aclaris Therapeutics Inc

You need the following data to determine equity ratio:

Balance sheet
Debt to equity ratio = total debt \ shareholders equity
47,794 \ 219,838 = 0.22 or 21.7%

Debt to equity measures the total debt versus the total shareholders equity. While the total debts to total assets ratio uses total assets, the debt to equity ratio looks at the total equity of shareholders. Where equity of shareholders are:

Common shares.
Preferred shares.
Retained earnings.

You can find the shareholders' equity in the balance sheet. A ratio between 0,5 and 1,5 is preferred. If the ratio is above 1.5, that would indicate creditors have significantly more stake (debt) in the company than the shareholders. In other words, the company is using a lot of debt to finance their operations.

Not all debt is equally risky. Meaning you can adjust the ratio by including or excluding certain amounts of debt. Short term debts are less risky because they have to be paid back within one year anyway. It’s much easier to plan one year ahead versus five or ten years.

2. Market Valuation of Aclaris Therapeutics Inc

2. Earnings Per Share

2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Aclaris Therapeutics Inc generates.

Above 15 is considered overpriced but always compare Aclaris Therapeutics Inc to the Diagnostics & Research industry mean.
A PE ratio of -52.60 means the investor is paying $-52.60 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aclaris Therapeutics Inc:

The EOD is -55.607. Company is losing money. -2
The MRQ is -52.600. Company is losing money. -2
The TTM is -50.404. Company is losing money. -2

Trends

Current period		Compared to		+/-
EOD	-55.607	MRQ	-52.600	-3.008
MRQ	-52.600	TTM	-50.404	-2.196
TTM	-50.404	YOY	-53.099	+2.695
TTM	-50.404	5Y	-31.851	-18.553
5Y	-31.851	10Y	-43.001	+11.150

Compared to industry (Diagnostics & Research)

Period	Company	Industry (mean)	+/-
EOD	-55.607	-1.994	-53.613
MRQ	-52.600	-2.312	-50.288
TTM	-50.404	-4.930	-45.474
YOY	-53.099	-0.548	-52.551
5Y	-31.851	-1.611	-30.240
10Y	-43.001	-1.973	-41.028

Measures how much money you pay for each share for every $1 in earnings Aclaris Therapeutics Inc generates.

Indicates if the company’s shares are under or overvalued.

How to use PE ratio

Above 15 is considered overpriced but is hard to determine. Always compare Aclaris Therapeutics Inc to the Diagnostics & Research industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use PE ratio in their analysis

The PE ratio tells investors the current sentiment in the market for that company. As with every stock, the stock price never shows the real valuation of a company but rather how the market thinks how much the stock is worth.

In other words, the current stock price also incorporates any future earnings or business opportunities in the future. The best example is the stock market crash in 2000. The PE ratio for any internet based company was going through the roof. Only based on the general assumption the internet and all associated businesses would thrive in the future. But this was based on nothing. A business still needs a good product or service to be able to survive. Instead, every investor bought any stock which did something related to the internet. Result: huge market crash.

Many investors were willing to pay premium prices and that was causing the PE ratio to rise. A high PE ratio is a warning sign that investors might be overvaluing a stock based on future earnings.

The three steps every investor should look at:

What is the current PE Ratio?
The current most recent quarter (MRQ) PE Ratio of Aclaris Therapeutics Inc is -52.60. This means the investor is paying $-52.60 for every $1 in earnings.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Diagnostics & Research industry is -2.31.
What is the trend?
The trend is important because it shows you how Aclaris Therapeutics Inc is performing over time. The most recent quarter might be important if Aclaris Therapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Aclaris Therapeutics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Some industries might have very high or very low PE ratios in general.
PE ratios can be high for several years, it does not mean a sudden collapse is imminent.
Earnings growth is not included in the PE ratio.

How to calculate PE ratio

PE ratio = market value per share \ earnings per share

Real life example Aclaris Therapeutics Inc

You need the following data to determine the PE ratio:

Balance sheet
Income statement

The PE ratio is a very commonly used ratio to determine the value of a company by comparing the current stock price relative to its earnings per share (EPS). Before we can calculate the PE ratio we need to know the EPS. EPS is calculated as follows:

EPS = (net profit - preferred dividends) \ end of period outstanding shares*
Net profit = revenue - expenses
\ 66,675 = EPS
PE ratio MRQ = -52.60

* The net profit minus preferred dividends can be found in the incomestatement as netIncomeApplicableToCommonShares.

The PE value helps investors to determine if the current stock price is under or overvalued. It also projects future growth.

In general, a higher PE ratio means that investors predict higher future growth. If the PE ratio is too high, then investors expect way too much future growth the company can never fulfil. This is most likely to happen in faster moving companies like tech companies or automobile companies like Tesla. These are hot and booming markets where investors expect much future growth driven by new technology (electric cars). When looking at the current MRQ (most recent quarter) PE ratio of Tesla ( jan. 2021) it's about 247 while the average in the industry is only 6. That might be a clue that Tesla is trading for way too high prices compared to their current assets and is more based on future growth.

2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Aclaris Therapeutics Inc.

Lower is better.
A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Aclaris Therapeutics Inc:

The MRQ is -1,806.039. Very Bad. -2
The TTM is -243.412. Very Bad. -2

Trends

Current period		Compared to		+/-
MRQ	-1,806.039	TTM	-243.412	-1,562.627
TTM	-243.412	YOY	142.734	-386.147
TTM	-243.412	5Y	43.259	-286.671
5Y	43.259	10Y	-211.235	+254.494

Compared to industry (Diagnostics & Research)

Period	Company	Industry (mean)	+/-
MRQ	-1,806.039	-0.052	-1,805.987
TTM	-243.412	0.036	-243.448
YOY	142.734	0.113	+142.621
5Y	43.259	0.023	+43.236
10Y	-211.235	0.023	-211.258

PEG Ratio	Meaning
0.5	You can buy the stock cheap based on future growth
1	You pay a fair price based on future growth
2	The stock is overpriced based on future growth

2. Book Value per Share

2.3. Price to Book Ratio

Measures if the stock price of Aclaris Therapeutics Inc is to cheap or to expensive compared to its book value.

At or below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
A PB ratio of 4.77 means the investor is paying $4.77 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Aclaris Therapeutics Inc:

The EOD is 5.047. Seems overpriced? -1
The MRQ is 4.774. Neutral. Compare to industry.
The TTM is 5.003. Seems overpriced? -1

Trends

Current period		Compared to		+/-
EOD	5.047	MRQ	4.774	+0.273
MRQ	4.774	TTM	5.003	-0.229
TTM	5.003	YOY	9.242	-4.239
TTM	5.003	5Y	5.007	-0.004
5Y	5.007	10Y	6.186	-1.179

Compared to industry (Diagnostics & Research)

Period	Company	Industry (mean)	+/-
EOD	5.047	2.021	+3.026
MRQ	4.774	2.205	+2.569
TTM	5.003	3.188	+1.815
YOY	9.242	4.346	+4.896
5Y	5.007	3.414	+1.593
10Y	6.186	3.056	+3.130

2. Total Gains per Share

2.4. Latest News of Aclaris Therapeutics Inc

Does Aclaris Therapeutics Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Aclaris Therapeutics Inc to keep up to date. Note: the news is often already included in the price.

Date	Title	Read
2022-11-08 14:25	Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates	Read

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Aclaris Therapeutics Inc.

3.1. Institutions holding Aclaris Therapeutics Inc

Institutions are holding 96.199% of the shares of Aclaris Therapeutics Inc.

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2022-06-30	Wellington Management Company LLP	7.3513	0.0138	4901263	-828990	-14.4669
2022-06-30	VR Adviser, LLC	6.8454	11.4991	4563962	0	0
2022-06-30	RA Capital Management, LLC	6.5972	1.6372	4398453	2580645	141.9647
2022-06-30	Bvf Inc	5.9644	2.681	3976543	0	0
2022-06-30	Rock Springs Capital Management LP	5.8903	1.5955	3927149	62115	1.6071
2022-06-30	Vanguard Group Inc	4.2202	0.0011	2813685	84865	3.11
2022-06-30	Foresite Capital Management IV, LLC	4.2117	10.5551	2808034	-91000	-3.139
2022-06-30	COMMODORE CAPITAL LP	3.6157	7.115	2410622	95974	4.1464
2022-06-30	Orbimed Advisors, LLC	3.488	0.5882	2325500	745600	47.1929
2022-06-30	Holocene Advisors, LP	3.0911	0.1738	2060918	0	0
2022-06-30	Point72 Asset Management, L.P.	2.6007	0.1021	1733900	-543200	-23.8549
2022-06-30	LAURION CAPITAL MANAGEMENT LP	2.1599	0.3105	1440075	0	0
2022-06-30	Renaissance Technologies Corp	1.9944	0.022	1329678	-127900	-8.7748
2022-06-30	Foresite Capital Management V, LLC	1.8872	12.2711	1258243	0	0
2022-06-30	FMR Inc	1.8633	0.0017	1242308	28958	2.3866
2022-06-30	State Street Corporation	1.8452	0.001	1230241	146851	13.5548
2022-06-30	Deutsche Bank AG	1.7619	0.0092	1174701	-292402	-19.9306
2022-06-30	TCG Crossover Management, LLC	1.7173	6.7893	1144939	0	0
2022-06-30	Great Point Partners LLC	1.6244	3.626	1083000	140555	14.9139
2022-06-30	Geode Capital Management, LLC	1.4357	0.002	957216	110825	13.0938
Total		70.1653	58.9947	46780430	+2112896	+4.5%

3.2. Funds holding Aclaris Therapeutics Inc

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2022-10-31	Vanguard Total Stock Mkt Idx Inv	2.6803	0.0024	1786979	0	0
2022-09-30	Vanguard Instl Ttl Stck Mkt Idx Tr	2.6803	0.0027	1786979	24840	1.4097
2022-10-31	iShares Russell 2000 ETF	2.1637	0.0423	1442596	4712	0.3277
2022-07-31	Biotech Growth Ord	1.8426	4.1002	1228500	0	0
2022-10-31	Vanguard Extended Market Index Investor	1.0668	0.0133	711276	6862	0.9741
2022-10-31	iShares Russell 2000 Growth ETF	0.7713	0.0833	514221	-2412	-0.4669
2022-08-31	Fidelity® Small Cap Index	0.6898	0.039	459921	7835	1.7331
2022-10-31	iShares Biotechnology ETF	0.5941	0.0766	396077	1896	0.481
2022-09-30	Fidelity® Select Biotechnology	0.4627	0.0955	308483	-127106	-29.1803
2022-09-30	State St Russell Sm/Mid Cp® Indx NL Cl C	0.4564	0.0161	304300	20500	7.2234
2022-09-30	Fidelity® VIP Growth Initial	0.4183	0.0677	278900	0	0
2022-09-30	Fidelity® Extended Market Index	0.3857	0.0145	257185	0	0
2022-09-30	State St Russell Sm Cap® Indx NL Cl C	0.3556	0.0451	237084	21076	9.757
2022-09-30	Hartford Small Company Y	0.3555	0.6066	236997	0	0
2022-09-30	Fidelity® Capital Appreciation	0.327	0.0693	218000	0	0
2022-10-31	Schwab US Small-Cap ETF™	0.3209	0.0246	213966	0	0
2022-09-30	Hartford Small Cap Growth HLS IA	0.2905	0.45	193663	-71010	-26.8293
2022-09-30	NT R2000 Growth Index Fund - NL	0.2887	0.0901	192514	15126	8.5271
2022-09-30	NT R2000 Index Fund - NL	0.2777	0.0463	185125	14383	8.4238
2022-04-30	United Global Healthcare SGD Acc	0.2638	0.3978	175852	46702	36.1611
Total		16.6917	6.2834	11128618	-36596	-0.3%

3.3. Insider Transactions

Insiders are holding 3.025% of the shares of Aclaris Therapeutics Inc.

Date	Owner	Type	Amount	Price	Post Transaction Amount
2022-10-26	Andrew N Schiff	SELL	14540	17	488381
2022-10-24	Andrew N Schiff	SELL	14616	17.01	514939
2022-10-17	Andrew N Schiff	SELL	19944	16.05	561648
2022-10-17	Joseph Monahan	SELL	5000	15.98	101386
2022-10-06	Andrew N Schiff	SELL	37839	16.54	588916
2022-10-04	Andrew N Schiff	SELL	7700	16.01	626755
2022-06-17	Andrew N. Schiff	SELL	19565	15.14
2022-04-25	Neal Walker	SELL	20000	15.18	1245763
2022-04-21	Neal Walker	SELL	25000	15.24	1290763
2022-04-18	Joseph Monahan	SELL	30000	16.28	106386
2022-03-11	Neal Walker	SELL	56303	15.91
2022-03-10	Frank Ruffo	SELL	12823	15.55
2022-03-10	Joseph Monahan	SELL	27165	15.71
2022-02-09	Joseph Monahan	SELL	383	12.68
2021-07-13	David N Gordon	SELL	2631	16.98	147447
2021-06-03	Kamil Ali-jackson	SELL	9492	21.96	122196
2021-06-02	Neal Walker	SELL	33260	21.64	1265442
2021-06-01	David N Gordon	SELL	14000	23.01	195992
2021-05-07	Kamil Ali-jackson	SELL	5416	23.52	158618
2021-05-05	Kamil Ali-jackson	SELL	15000	23.98	158618

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Aclaris Therapeutics Inc compared to the Most Recent Quarter (MRQ).

	End of day	+/-	Most Recent Quarter	Trailing 12 Months	+/-	Year-Over-Year	+/-	5 Year	+/-	10 Year	+/-
Book Value Change Per Share	-	-	-0.239	0.012	-2063%	0.659	-136%	-0.018	-92%	0.097	-346%
Book Value Growth	-	-	-0.072	-0.007	-90%	0.256	-128%	-0.058	-20%	0.027	-367%
Book Value Per Share	-	-	3.297	3.124	+6%	2.251	+46%	2.263	+46%	1.794	+84%
Book Value Per Share Growth	-	-	-0.072	-0.007	-90%	0.256	-128%	-0.058	-20%	0.027	-367%
Current Ratio	-	-	12.535	12.220	+3%	10.212	+23%	8.426	+49%	12.277	+2%
Debt To Asset Ratio	-	-	0.179	0.187	-5%	0.285	-37%	0.262	-32%	0.355	-50%
Debt To Equity Ratio	-	-	0.217	0.232	-6%	0.441	-51%	0.396	-45%	0.331	-34%
Dividend Per Share	-	-	-	-	0%	-	0%	-	0%	-	0%
Eps	-	-	-0.299	-0.308	+3%	-0.305	+2%	-0.397	+33%	-0.333	+11%
Eps Growth	-	-	0.029	0.021	+37%	-0.073	+349%	0.076	-61%	0.245	-88%
Gross Profit Margin	-	-	1.000	1.000	0%	1.005	-1%	1.094	-9%	1.026	-3%
Net Profit Margin	-	-	-1.049	-10.652	+915%	-11.805	+1025%	-14.613	+1293%	-9.378	+794%
Operating Margin	-	-	-1.098	-10.665	+872%	-11.834	+978%	-14.712	+1240%	-9.437	+760%
Operating Ratio	-	-	2.098	12.172	-83%	9.579	-78%	13.370	-84%	8.701	-76%
Pb Ratio	5.047	+5%	4.774	5.003	-5%	9.242	-48%	5.007	-5%	6.186	-23%
Pe Ratio	-55.607	-6%	-52.600	-50.404	-4%	-53.099	+1%	-31.851	-39%	-43.001	-18%
Peg Ratio	-	-	-1806.039	-243.412	-87%	142.734	-1365%	43.259	-4275%	-211.235	-88%
Price Per Share	16.640	+5%	15.740	15.370	+2%	16.808	-6%	11.458	+37%	12.618	+25%
Price To Total Gains Ratio	-69.662	-6%	-65.895	-41.645	-37%	-44.082	-33%	-30.894	-53%	-24.811	-62%
Profit Growth	-	-	2.907	2.129	+37%	-7.265	+350%	6.993	-58%	0.026	+11284%
Quick Ratio	-	-	21.985	19.048	+15%	15.977	+38%	13.317	+65%	20.515	+7%
Return On Assets	-	-	-0.075	-0.081	+8%	-0.127	+70%	-0.145	+94%	-0.135	+82%
Return On Equity	-	-	-0.091	-0.099	+10%	-0.195	+115%	-0.213	+135%	-0.167	+84%
Revenue Growth	-	-	0.920	0.208	+343%	0.030	+2963%	-0.148	+116%	-0.093	+110%
Total Gains Per Share	-	-	-0.239	0.012	-2063%	0.659	-136%	-0.018	-92%	0.097	-346%
Total Gains Per Share Growth	-	-	-4.488	-0.790	-82%	-1.213	-73%	-0.621	-86%	-1.084	-76%
Usd Book Value	-	-	219838000.000	208282500.000	+6%	150085000.000	+46%	150891350.000	+46%	119586617.647	+84%
Usd Book Value Change Per Share	-	-	-0.239	0.012	-2063%	0.659	-136%	-0.018	-92%	0.097	-346%
Usd Book Value Per Share	-	-	3.297	3.124	+6%	2.251	+46%	2.263	+46%	1.794	+84%
Usd Dividend Per Share	-	-	-	-	0%	-	0%	-	0%	-	0%
Usd Eps	-	-	-0.299	-0.308	+3%	-0.305	+2%	-0.397	+33%	-0.333	+11%
Usd Price Per Share	16.640	+5%	15.740	15.370	+2%	16.808	-6%	11.458	+37%	12.618	+25%
Usd Profit	-	-	-19952000.000	-20519250.000	+3%	-20308500.000	+2%	-25908950.000	+30%	-18754852.941	-6%
Usd Revenue	-	-	19018000.000	5875000.000	+224%	1710000.000	+1012%	2965800.000	+541%	1764705.882	+978%
Usd Total Gains Per Share	-	-	-0.239	0.012	-2063%	0.659	-136%	-0.018	-92%	0.097	-346%
	EOD	+2 -3	MRQ	TTM	+23 -9	YOY	+22 -11	5Y	+21 -12	10Y	+21 -12

4.2. Fundamental Score

Let's check the fundamental score of Aclaris Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

Indicator	Condition		Value
Price to Earnings Ratio (EOD)	Between	0-15	-55.607
Price to Book Ratio (EOD)	Between	0-1	5.047
Net Profit Margin (MRQ)	Greater than	0	-1.049
Operating Margin (MRQ)	Greater than	0	-1.098
Quick Ratio (MRQ)	Greater than	1	21.985
Current Ratio (MRQ)	Greater than	1	12.535
Debt to Asset Ratio (MRQ)	Less than	1	0.179
Debt to Equity Ratio (MRQ)	Less than	1	0.217
Return on Equity (MRQ)	Greater than	0.15	-0.091
Return on Assets (MRQ)	Greater than	0.05	-0.075
Total			4/10 (40.0%)

Create your own Stock Scanner

Investing is personal. The best investors buy stocks based on their own analysis. Create your personal Stock Scanner with the key performance indicators that are important to you.
Create your own Stock Scanner

4.3. Technical Score

Let's check the technical score of Aclaris Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Open	Greater than	Close	15.720
Total			0/1 (0.0%)

Create your own Symbol Scanner

Trading is personal. The best traders buy and sell based on their own technical analysis. Create your personal Symbol Scanner with the technical indicators that are important to you.
Create your own Symbol Scanner

Latest Balance Sheet

Balance Sheet of 2022-09-30. Currency in USD. All numbers in thousands.

Summary

Total Assets	267,632
Total Liabilities	47,794
Total Stockholder Equity	219,838

	As reported
Total Liabilities	47,794
Total Stockholder Equity	+ 219,838
Total Assets	= 267,632

Assets

Total Assets	267,632
Total Current Assets	248,062
Long-term Assets	248,062

Total Current Assets

Total Current Assets (as reported)	248,062
Cash And Cash Equivalents	61,653
Short-term Investments	186,409
Net Receivables	597
Total Current Assets (calculated)	248,659
+/-	597

Long-term Assets

Long-term Assets (as reported)	11,059
Property Plant Equipment	1,145
Intangible Assets	6,992
Long-term Assets Other	2,922
Long-term Assets (calculated)	11,059
+/-	0

Liabilities & Shareholders' Equity

Total Current Liabilities	19,789
Long-term Liabilities	28,005
Total Stockholder Equity	219,838

Total Current Liabilities

Total Current Liabilities (as reported)	19,789
Short-term Debt	766
Accounts payable	7,667
Other Current Liabilities	19,789
Total Current Liabilities (calculated)	28,222
+/-	8,433

Long-term Liabilities

Long-term Liabilities (as reported)	28,005
Long-term Liabilities (calculated)	0
+/-	28,005

Total Stockholder Equity

Total Stockholder Equity (as reported)	219,838
Retained Earnings	-654,680
Accumulated Other Comprehensive Income	-1,465
Total Stockholder Equity (calculated)	-656,145
+/-	875,983

Other

Cash and Short Term Investments	248,062
Common Stock Shares Outstanding	66,675
Liabilities and Stockholders Equity	267,632
Net Debt	-60,887
Short Long Term Debt Total	766

Balance Sheet

Currency in USD. All numbers in thousands.

Trend

2022-09-30

2022-06-30

2022-03-31

2021-12-31

2021-09-30

2021-06-30

2021-03-31

2020-12-31

2020-09-30

2020-06-30

2020-03-31

2019-12-31

2019-09-30

2019-06-30

2019-03-31

2018-12-31

2018-09-30

2018-06-30

2018-03-31

2017-12-31

2017-09-30

2017-06-30

2017-03-31

2016-12-31

2016-09-30

2016-06-30

2016-03-31

2015-12-31

2015-09-30

2015-06-30

2015-03-31

2014-12-31

2014-09-30

2013-12-31

> Total Assets

14,207
0
17,377
0
12,223
42,087
94,076
87,270
96,092
86,071
176,085
166,210
176,808
261,391
243,509
220,622
201,819
176,176
275,566
253,183
217,239
160,416
98,297
96,812
84,999
71,902
70,784
161,399
288,046
263,494
251,211
226,527
277,976
267,632

267,632

277,976

226,527

251,211

263,494

288,046

161,399

70,784

71,902

84,999

96,812

98,297

160,416

217,239

253,183

275,566

176,176

201,819

220,622

243,509

261,391

176,808

166,210

176,085

86,071

96,092

87,270

94,076

42,087

12,223

17,377

14,207

> Total Current Assets

0
0
16,334
0
10,444
39,360
86,524
86,833
95,638
85,590
138,556
157,349
175,751
234,122
200,221
192,256
171,172
145,519
179,499
156,813
137,894
145,370
83,803
82,714
70,955
57,997
57,493
134,501
241,261
205,782
205,032
190,881
259,354
248,062

248,062

259,354

190,881

205,032

205,782

241,261

134,501

57,493

57,997

70,955

82,714

83,803

145,370

137,894

156,813

179,499

145,519

171,172

192,256

200,221

234,122

175,751

157,349

138,556

85,590

95,638

86,833

86,524

39,360

10,444

16,334

Cash And Cash Equivalents

9,588
0
10,757
0
9,853
25,419
9,851
13,131
31,815
17,796
30,171
23,677
32,708
60,055
20,202
54,881
46,035
26,590
57,019
34,197
31,654
29,898
35,937
53,992
32,587
23,643
22,063
35,267
113,447
53,602
27,349
36,342
68,264
61,653

61,653

68,264

36,342

27,349

53,602

113,447

35,267

22,063

23,643

32,587

53,992

35,937

29,898

31,654

34,197

57,019

26,590

46,035

54,881

20,202

60,055

32,708

23,677

30,171

17,796

31,815

13,131

9,851

25,419

9,853

10,757

9,588

Short-term Investments

3,736
0
5,373
0
0
12,986
75,017
72,115
62,195
66,246
107,051
129,741
137,789
167,793
173,655
132,096
118,569
107,681
110,953
102,558
83,863
61,530
39,078
25,013
35,528
29,834
32,068
93,028
118,227
144,280
164,065
143,280
180,339
186,409

186,409

180,339

143,280

164,065

144,280

118,227

93,028

32,068

29,834

35,528

25,013

39,078

61,530

83,863

102,558

110,953

107,681

118,569

132,096

173,655

167,793

137,789

129,741

107,051

66,246

62,195

72,115

75,017

12,986

5,373

3,736

Net Receivables

0
0
0
0
0
23
22
20
20
20
20
20
20
658
481
529
2,182
1,033
4,861
15,817
19,370
673
704
933
775
887
772
817
939
811
623
633
637
597

597

637

633

623

811

939

817

772

887

775

933

704

673

19,370

15,817

4,861

1,033

2,182

529

481

658

Inventory

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,026
1,044
791
856
185
0
0
0
0
0
0
0
0
0
0
0
0
0

185

856

791

1,044

1,026

> Long-term Assets

0
0
1,043
0
1,779
2,727
7,552
437
454
481
37,529
8,861
1,057
27,269
43,288
28,366
30,647
30,657
96,067
96,370
79,345
15,046
14,494
14,098
14,044
13,905
13,291
26,898
46,785
57,712
46,179
35,646
18,622
11,059

11,059

18,622

35,646

46,179

57,712

46,785

26,898

13,291

13,905

14,044

14,098

14,494

15,046

79,345

96,370

96,067

30,657

30,647

28,366

43,288

27,269

1,057

8,861

37,529

481

454

437

7,552

2,727

1,779

1,043

Property Plant Equipment

19
0
515
0
641
761
360
417
434
461
481
706
938
1,203
2,159
2,191
4,375
4,409
4,280
4,026
4,241
2,854
2,470
2,187
2,230
1,920
1,654
1,424
1,287
1,170
1,335
1,277
1,276
1,145

1,145

1,276

1,277

1,335

1,170

1,287

1,424

1,654

1,920

2,230

2,187

2,470

2,854

4,241

4,026

4,280

4,409

4,375

2,191

2,159

1,203

938

706

481

461

434

417

360

761

641

515

Goodwill

0
0
0
0
0
0
0
0
0
0
0
0
0
18,504
18,504
18,504
18,504
18,504
18,504
18,504
0
0
0
0
0
0
0
0
0
0
0
0
0
0

18,504

Long Term Investments

0
0
518
0
0
0
7,170
0
0
0
36,912
0
0
0
14,997
0
0
0
0
0
0
0
0
0
0
0
0
14,362
34,503
45,735
34,242
23,955
7,221
0

7,221

23,955

34,242

45,735

34,503

14,362

14,997

36,912

7,170

518

Intangible Assets

0
0
0
0
0
0
0
0
0
0
0
0
0
7,367
7,349
7,330
7,311
7,292
72,951
71,459
69,781
7,217
7,199
7,180
7,161
7,142
7,123
7,105
7,086
7,067
7,048
7,030
7,011
6,992

6,992

7,011

7,030

7,048

7,067

7,086

7,105

7,123

7,142

7,161

7,180

7,199

7,217

69,781

71,459

72,951

7,292

7,311

7,330

7,349

7,367

Long-term Assets Other

0
0
10
0
1,138
1,966
22
20
20
20
136
136
119
195
279
341
457
452
332
2,381
5,323
4,975
4,825
4,731
4,653
4,843
4,514
4,007
3,909
3,740
3,554
3,384
3,114
2,922

2,922

3,114

3,384

3,554

3,740

3,909

4,007

4,514

4,843

4,653

4,731

4,825

4,975

5,323

2,381

332

452

457

341

279

195

119

136

1,966

1,138

> Total Liabilities

370
0
38,132
0
1,427
80,205
1,555
4,059
5,852
4,949
6,595
5,921
8,664
17,132
18,247
20,150
27,616
29,848
60,442
70,930
80,009
75,141
28,385
38,637
35,633
31,145
33,134
49,105
54,231
46,913
53,870
46,328
42,224
47,794

47,794

42,224

46,328

53,870

46,913

54,231

49,105

33,134

31,145

35,633

38,637

28,385

75,141

80,009

70,930

60,442

29,848

27,616

20,150

18,247

17,132

8,664

5,921

6,595

4,949

5,852

4,059

1,555

80,205

1,427

38,132

370

> Total Current Liabilities

367
0
1,451
0
1,424
1,897
1,555
3,729
5,507
4,591
6,223
5,637
8,369
9,993
12,762
13,823
20,069
22,280
27,342
36,228
42,748
38,989
22,432
20,603
17,745
12,788
14,874
14,505
14,916
17,839
22,931
16,726
16,217
19,789

19,789

16,217

16,726

22,931

17,839

14,916

14,505

14,874

12,788

17,745

20,603

22,432

38,989

42,748

36,228

27,342

22,280

20,069

13,823

12,762

9,993

8,369

5,637

6,223

4,591

5,507

3,729

1,555

1,897

1,424

1,451

367

Short-term Debt

0
0
0
0
0
0
0
0
0
0
0
0
0
0
142
142
552
591
601
868
991
642
637
624
610
591
603
625
647
669
1,386
716
741
766

766

741

716

1,386

669

647

625

603

591

610

624

637

642

991

868

601

591

552

142

Short Long Term Debt

0
0
0
0
0
0
0
0
0
0
0
0
0
0
142
142
552
0
0
373
0
0
0
0
0
0
0
0
0
0
0
0
0
0

373

552

142

Accounts payable

353
0
1,263
0
957
958
810
2,808
3,309
1,774
2,845
3,604
5,848
6,483
7,822
8,155
12,504
13,735
14,755
14,574
14,160
17,780
9,917
6,946
5,502
5,081
5,254
7,292
4,244
7,564
9,985
8,121
5,703
7,667

7,667

5,703

8,121

9,985

7,564

4,244

7,292

5,254

5,081

5,502

6,946

9,917

17,780

14,160

14,574

14,755

13,735

12,504

8,155

7,822

6,483

5,848

3,604

2,845

1,774

3,309

2,808

810

958

957

1,263

353

Other Current Liabilities

14
0
188
0
467
939
745
921
2,198
2,817
3,378
2,033
2,521
3,510
4,798
5,526
7,013
7,954
11,986
20,786
27,597
20,567
11,878
13,033
11,633
7,116
9,017
6,588
10,025
9,606
22,931
7,889
9,773
19,789

19,789

9,773

7,889

22,931

9,606

10,025

6,588

9,017

7,116

11,633

13,033

11,878

20,567

27,597

20,786

11,986

7,954

7,013

5,526

4,798

3,510

2,521

2,033

3,378

2,817

2,198

921

745

939

467

188

> Long-term Liabilities

0
0
36,681
0
3
78,308
0
330
345
358
372
284
295
7,139
5,485
6,327
7,547
7,568
33,100
34,702
37,261
36,152
5,953
18,034
17,888
18,357
18,260
34,600
39,315
29,074
30,939
29,602
26,007
28,005

28,005

26,007

29,602

30,939

29,074

39,315

34,600

18,260

18,357

17,888

18,034

5,953

36,152

37,261

34,702

33,100

7,568

7,547

6,327

5,485

7,139

295

284

372

358

345

330

78,308

36,681

Long term Debt Total

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
29,914
29,918
29,924
30,089
21
10,573
10,573
10,613
10,653
10,692
10,731
0
0
0
0
0

10,731

10,692

10,653

10,613

10,573

30,089

29,924

29,918

29,914

Warrants

0
0
0
0
0
78,305
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

78,305

Long-term Liabilities Other

0
0
0
0
0
0
0
330
345
358
372
284
295
0
4,936
5,778
6,998
7,019
2,637
4,235
6,788
5,673
5,404
6,912
6,766
7,195
7,240
23,541
28,217
28,707
30,572
29,235
25,640
0

25,640

29,235

30,572

28,707

28,217

23,541

7,240

7,195

6,766

6,912

5,404

5,673

6,788

4,235

2,637

7,019

6,998

5,778

4,936

295

284

372

358

345

330

Deferred Long Term Liability

0
0
4
0
0
0
0
0
0
0
0
0
0
0
549
549
549
549
549
549
0
0
549
549
549
549
367
367
367
367
367
367
367
0

367

549

> Total Stockholder Equity

13,837
0
-20,755
0
10,796
-38,118
92,521
83,211
90,240
81,122
169,490
160,289
168,144
244,259
225,262
200,472
174,203
146,328
215,124
182,253
137,230
85,275
69,912
58,175
49,366
40,757
37,650
112,294
233,815
216,581
197,341
180,199
235,752
219,838

219,838

235,752

180,199

197,341

216,581

233,815

112,294

37,650

40,757

49,366

58,175

69,912

85,275

137,230

182,253

215,124

146,328

174,203

200,472

225,262

244,259

168,144

160,289

169,490

81,122

90,240

83,211

92,521

-38,118

10,796

-20,755

13,837

Common Stock

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
66,679,641

66,679,641

Retained Earnings Total Equity

-634,728

-614,196

-595,407

-572,603

-551,457

-533,296

-504,542

-491,369

-480,710

-469,113

-453,527

-329,738

-292,173

-253,622

-220,882

-189,664

-159,435

-136,501

-118,309

-103,471

-90,912

-79,437

-68,743

-55,872

-42,833

-38,119

Accumulated Other Comprehensive Income

0
0
-6
0
-52
1
-149
3
1
-54
-269
-249
-166
-113
-246
-328
-188
-116
-69
-49
8
-1
-66
47
15
-44
-94
-140
-184
-3
-224
-972
-1,326
-1,465

-1,465

-1,326

-972

-224

-3

-184

-140

-94

-44

-66

-1

-49

-69

-116

-188

-328

-246

-113

-166

-249

-269

-54

-149

-52

-6

Capital Surplus

0
0
0
0
0
0
135,503
139,080
158,982
160,613
260,671
264,009
286,619
380,873
384,943
390,464
395,273
400,066
507,366
512,040
516,836
520,209
523,505
527,241
530,061
532,170
542,286
645,730
785,455
789,186
792,971
795,366
871,805
0

871,805

795,366

792,971

789,186

785,455

645,730

542,286

532,170

530,061

527,241

523,505

520,209

516,836

512,040

507,366

400,066

395,273

390,464

384,943

380,873

286,619

264,009

260,671

160,613

158,982

139,080

135,503

Treasury Stock

Other Stockholders Equity

0
0
21
0
38,062
85
135,396
139,146
159,073
160,681
260,528
263,936
286,681
381,091
385,177
390,819
396,064
401,295
508,968
514,064
519,309
522,361
525,505
529,652
15
535,063
542,286
648,443
785,455
789,186
197,565
795,366
871,805
875,982

875,982

871,805

795,366

197,565

789,186

785,455

648,443

542,286

535,063

529,652

525,505

522,361

519,309

514,064

508,968

401,295

396,064

390,819

385,177

381,091

286,681

263,936

260,528

160,681

159,073

139,146

135,396

38,062

Balance Sheet

Currency in USD. All numbers in thousands.

	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Accounts Payable	9,985	5,254	9,917	14,755	7,822	2,845	810	1,263	353
Accumulated Other Comprehensive Income	-224	-94	-66	-69	-246	-269	-149	-6	3
Additional Paid In Capital	-	-	-	-	0	0	0	-	-
Capital Lease Obligations	693	603	637	601	142	-	-	-	-
Capital Stock	1	0	0	0	-	-	-	-	-
Capital Surpluse	792,971	542,286	523,505	507,366	384,943	260,671	135,503	-	-
Cash	27,349	22,063	35,937	57,019	20,202	30,171	9,851	10,757	9,588
Cash And Short Term Investments	27,349	54,131	75,015	167,972	193,857	137,222	84,868	16,130	13,324
Common Stock	1	-	-	-	0	0	0	-	-
Common Stock Shares Outstanding	42,539	42,539	41,324	32,910	28,102	21,416	6,107	9,262	10,655
Common Stock Total Equity	1	-	-	-	0	0	0	-	-
Deferred Long Term Liab	367	367	549	549	62	0	0	4	-
Good Will	-	-	0	18,504	18,504	0	0	-	-
Intangible Assets	7,048	7,123	7,199	72,951	7,349	0	0	-	-
Inventory	-	-	-	791	0	0	0	-	-
Liabilities And Stockholders Equity	251,211	70,784	98,297	275,566	243,509	176,085	94,076	17,377	14,207
Long Term Debt	-	10,653	-	29,914	261	0	0	-	-
Long Term Debt Total	-	10,653	21	29,914	-	-	-	-	-
Long Term Investments	34,242	-	-	0	14,997	36,912	7,170	518	-
Net Debt	-26,656	-10,807	-35,300	-26,504	-20,060	-30,171	-9,851	-10,757	-9,588
Net Invested Capital	197,341	48,303	69,912	245,038	225,262	-	-	-	-
Net Receivables	623	772	704	4,861	481	-	22	-	-
Net Tangible Assets	190,293	30,527	62,713	189,346	199,409	169,490	92,521	-20,755	-
Net Working Capital	182,101	42,619	61,371	152,157	187,459	-	-	-	-
Non Current Assets Total	46,179	13,291	14,494	96,067	43,288	37,529	7,552	1,043	821
Non Current Liabilities Other	30,572	7,240	5,404	2,637	4,936	372	-	-	-
Non Current Liabilities Total	30,939	18,260	5,953	33,100	5,485	372	-	36,681	23,003
Non Currrent Assets Other	3,554	4,514	4,825	332	279	136	22	10	-
Noncontrolling Interest In Consolidated Entity	-	-	-	-	0	0	0	-	-
Other Assets	251,211	4,514	92	68,002	279	136	22	10	-
Other Current Assets	12,995	2,590	8,084	5,875	5,883	1,334	1,656	204	62
Other Current Liab	22,931	9,017	11,878	11,986	4,798	3,378	745	188	14
Other Liab	28,767	7,607	2,384	3,186	5,485	372	372	4	3
Other Stockholder Equity	197,565	542,286	523,505	507,366	385,177	260,528	135,396	21	18
Preferred Stock Total Equity	-	-	-	-	0	0	0	36,677	23,000
Property Plant And Equipment Gross	-	1,654	2,470	4,280	2,159	481	360	515	19
Property Plant And Equipment Net	1,335	1,654	2,470	4,280	2,159	481	360	515	19
Property Plant Equipment	1,335	1,654	7,203	2,287	2,159	481	360	515	19
Retained Earnings	-595,407	-504,542	-453,527	-292,173	-159,435	-90,912	-42,833	-20,749	-9,166
Retained Earnings Total Equity	-595,407	-504,542	-453,527	-292,173	-159,435	-90,912	-42,833	-	-
Short Long Term Debt	-	-	-	-	142	-	-	-	-
Short Long Term Debt Total	693	11,256	637	30,515	142	-	-	-	-
Short Term Debt	1,386	603	637	601	142	-	-	-	-
Short Term Investments	164,065	32,068	39,078	110,953	173,655	107,051	75,017	5,373	3,736
Temporary Equity Redeemable Noncontrolling Interests	-	-	-	-	0	0	0	-	-
Total Assets	251,211	70,784	98,297	275,566	243,509	176,085	94,076	17,377	14,207
Total Current Assets	205,032	57,493	83,803	179,499	200,221	138,556	86,524	16,334	13,386
Total Current Liabilities	22,931	14,874	22,432	27,342	12,762	6,223	1,555	1,451	367
Total Liab	53,870	33,134	28,385	60,442	18,247	6,595	1,555	38,132	23,370
Total Permanent Equity	-	-	-	-	0	0	0	-	-
Total Stockholder Equity	197,341	37,650	69,912	215,124	225,262	169,490	92,521	-20,755	-9,163
Treasury Stock	-	-	-	-	0	0	0	-	-

	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2013-12-31
Accounts Payable	7,667	5,703	8,121	9,985	7,564	4,244	7,292	5,254	5,081	5,502	6,946	9,917	17,780	14,160	14,574	14,755	13,735	12,504	8,155	7,822	6,483	5,848	3,604	2,845	1,774	3,309	2,808	810	958	957	-	1,263	-	353
Accumulated Other Comprehensive Income	-1,465	-1,326	-972	-224	-3	-184	-140	-94	-44	15	47	-66	-1	8	-49	-69	-116	-188	-328	-246	-113	-166	-249	-269	-54	1	3	-149	1	-52	-	-6	-	-
Additional Paid In Capital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Capital Lease Obligations	-	741	716	693	669	647	625	603	591	610	624	637	642	991	868	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Capital Stock	-	1	1	1	1	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Capital Surpluse	-	871,805	795,366	792,971	789,186	785,455	645,730	542,286	532,170	530,061	527,241	523,505	520,209	516,836	512,040	507,366	400,066	395,273	390,464	384,943	380,873	286,619	264,009	260,671	160,613	158,982	139,080	135,503	-	-	-	-	-	-
Cash	61,653	68,264	36,342	27,349	53,602	113,447	35,267	22,063	23,643	32,587	53,992	35,937	29,898	31,654	34,197	57,019	26,590	46,035	54,881	20,202	60,055	32,708	23,677	30,171	17,796	31,815	13,131	9,851	25,419	9,853	-	10,757	-	9,588
Cash And Short Term Investments	248,062	248,603	179,622	27,349	197,882	231,674	128,295	54,131	53,477	68,115	79,005	75,015	91,428	115,517	136,755	167,972	134,271	164,604	186,977	193,857	227,848	170,497	153,418	137,222	84,042	94,010	85,246	84,868	38,405	9,853	-	16,130	-	-
Common Stock	66,679,641	1	1	1	1	1	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Common Stock Shares Outstanding	66,675	65,990	61,431	61,228	61,219	53,968	50,338	43,588	42,803	42,134	41,618	41,406	41,364	41,275	41,249	38,761	30,982	30,945	30,886	30,839	28,835	26,595	26,081	23,391	21,416	20,663	20,172	17,832	19,408	19,408	10,655	10,655	10,655	-
Common Stock Total Equity	-	1	1	1	1	1	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Deferred Long Term Liab	-	367	367	367	367	367	367	367	549	549	549	549	-	-	549	549	549	549	549	549	0	0	0	0	0	0	0	0	-	-	-	4	-	-
Good Will	-	-	-	-	-	-	-	-	-	-	-	0	0	0	18,504	18,504	18,504	18,504	18,504	18,504	18,504	0	0	0	0	0	0	0	-	-	-	-	-	-
Intangible Assets	6,992	7,011	7,030	7,048	7,067	7,086	7,105	7,123	7,142	7,161	7,180	7,199	7,217	69,781	71,459	72,951	7,292	7,311	7,330	7,349	7,367	0	0	0	0	0	0	0	-	-	-	-	-	-
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	0	185	856	791	1,044	1,026	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Liabilities And Stockholders Equity	267,632	277,976	226,527	251,211	263,494	288,046	161,399	70,784	71,902	84,999	96,812	98,297	160,416	217,239	253,183	275,566	176,176	201,819	220,622	243,509	261,391	176,808	166,210	176,085	86,071	96,092	87,270	94,076	42,087	12,223	-	17,377	-	-
Long Term Debt	-	-	-	-	-	10,731	10,692	10,653	10,613	10,573	10,573	-	29,930	29,924	29,918	29,914	0	0	0	261	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Long Term Debt Total	-	-	-	-	-	10,731	10,692	10,653	10,613	10,573	10,573	21	30,089	29,924	29,918	29,914	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Investments	-	7,221	23,955	34,242	45,735	34,503	14,362	-	-	-	-	-	-	-	-	-	-	-	-	14,997	-	-	-	36,912	-	-	-	7,170	-	-	-	518	-	-
Net Debt	-60,887	-67,523	-35,626	-26,656	-52,933	-102,069	-23,950	-10,807	-12,439	-21,404	-42,795	-35,300	674	-739	-3,411	-26,504	-25,999	-45,483	-54,739	-20,060	-60,055	-32,708	-23,677	-30,171	-17,796	-31,815	-13,131	-9,851	-25,419	-9,853	-	-10,757	-	-
Net Invested Capital	-	235,752	180,199	197,341	216,581	244,546	122,986	48,303	51,370	59,939	68,748	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Receivables	597	637	633	623	811	939	817	772	887	775	933	704	673	19,370	15,817	4,861	1,033	2,182	529	481	658	20	20	20	20	20	20	22	23	-	-	-	-	-
Net Tangible Assets	-	228,741	173,169	190,293	209,514	226,729	105,189	30,527	33,615	42,205	50,995	62,713	78,058	67,449	92,290	123,669	120,532	148,388	174,638	199,409	244,259	168,144	160,289	169,490	81,122	90,240	83,211	92,521	40,187	-	-	-20,755	-	-
Net Working Capital	-	243,137	174,155	182,101	187,943	226,345	119,996	42,619	45,209	53,210	62,111	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non Current Assets Total	11,059	18,622	35,646	46,179	57,712	46,785	26,898	13,291	13,905	14,044	14,098	14,494	15,046	79,345	96,370	96,067	30,657	30,647	28,366	43,288	27,269	1,057	8,861	37,529	481	454	437	7,552	2,727	1,779	-	1,043	-	-
Non Current Liabilities Other	-	25,640	29,235	30,572	28,707	28,217	23,541	7,240	7,195	6,766	6,912	5,404	5,673	6,788	4,235	2,637	7,019	6,998	5,778	4,936	-	295	284	372	358	345	330	-	-	-	-	-	-	-
Non Current Liabilities Total	28,005	26,007	29,602	30,939	29,074	39,315	34,600	18,260	18,357	17,888	18,034	5,953	36,152	37,261	34,702	33,100	7,568	7,547	6,327	5,485	7,139	295	284	372	358	345	330	-	78,308	3	-	36,681	-	-
Non Currrent Assets Other	2,922	3,114	3,384	3,554	3,740	3,909	4,007	4,514	4,843	4,653	4,731	4,825	4,975	5,323	2,381	332	452	457	341	279	195	119	136	136	20	20	20	22	1,966	1,138	-	10	-	-
Noncontrolling Interest In Consolidated Entity	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Other Assets	19,570	22,152	22,950	251,211	125	119	46	4,514	551	229	151	92	93	293	2,381	332	452	457	341	41,129	26,066	119	8,155	37,048	20	20	20	7,192	1,966	1,138	-	528	-	802
Other Current Assets	7,914	10,114	10,626	12,995	7,089	8,648	5,389	2,590	3,633	2,065	2,776	8,084	53,269	2,822	3,385	5,875	9,171	3,360	4,750	5,883	5,616	5,254	3,931	1,334	1,548	1,628	1,587	1,656	955	591	-	204	-	62
Other Current Liab	19,789	9,773	7,889	22,931	9,606	10,025	6,588	9,017	7,116	11,633	13,033	11,878	20,567	27,597	20,786	11,986	7,954	7,013	5,526	4,798	3,510	2,521	2,033	3,378	2,817	2,198	921	745	939	467	-	188	-	14
Other Liab	-	24,187	27,587	28,767	26,691	26,025	21,178	7,607	4,692	4,062	4,057	2,384	2,377	2,370	1,632	3,186	7,568	7,547	6,327	4,675	4,753	295	284	372	358	345	330	372	3	3	-	4	-	3
Other Stockholder Equity	875,982	871,805	795,366	197,565	789,186	785,455	648,443	542,286	535,063	15	529,652	525,505	522,361	519,309	514,064	508,968	401,295	396,064	390,819	385,177	381,091	286,681	263,936	260,528	160,681	159,073	139,146	135,396	85	38,062	-	21	-	-
Preferred Stock Total Equity	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	78,305	38,010	-	36,677	-	23,000
Property Plant And Equipment Gross	-	-	-	-	-	1,287	1,424	1,654	1,920	2,230	2,187	2,470	2,854	4,241	4,026	4,280	4,409	4,375	2,191	2,159	1,203	938	706	481	461	434	417	360	761	641	-	515	-	-
Property Plant And Equipment Net	1,145	1,276	1,277	1,335	1,170	1,287	1,424	1,654	1,920	2,230	2,187	2,470	2,854	4,241	4,026	4,280	4,409	4,375	2,191	2,159	1,203	938	706	481	461	434	417	360	761	641	-	515	-	-
Property Plant Equipment	-	1,276	1,277	1,335	1,170	5,077	1,424	1,654	1,920	6,654	6,767	7,203	7,736	9,271	4,026	4,280	4,409	4,375	2,191	2,159	1,203	938	706	481	461	434	417	360	761	641	-	515	-	19
Retained Earnings	-654,680	-634,728	-614,196	-595,407	-572,603	-551,457	-533,296	-504,542	-491,369	-480,710	-469,113	-453,527	-434,933	-379,614	-329,738	-292,173	-253,622	-220,882	-189,664	-159,435	-136,501	-118,309	-103,471	-90,912	-79,437	-68,743	-55,872	-42,833	-38,119	-27,214	-	-20,749	-	-
Retained Earnings Total Equity	-	-634,728	-614,196	-595,407	-572,603	-551,457	-533,296	-504,542	-491,369	-480,710	-469,113	-453,527	-	-	-329,738	-292,173	-253,622	-220,882	-189,664	-159,435	-136,501	-118,309	-103,471	-90,912	-79,437	-68,743	-55,872	-42,833	-38,119	-	-	-	-	-
Short Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	373	-	-	552	142	142	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Short Long Term Debt Total	766	741	716	693	669	11,378	11,317	11,256	11,204	11,183	11,197	637	30,572	30,915	30,786	30,515	591	552	142	142	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Short Term Debt	766	741	716	1,386	669	647	625	603	591	610	624	637	642	991	868	601	591	552	142	142	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Short Term Investments	186,409	180,339	143,280	164,065	144,280	118,227	93,028	32,068	29,834	35,528	25,013	39,078	61,530	83,863	102,558	110,953	107,681	118,569	132,096	173,655	167,793	137,789	129,741	107,051	66,246	62,195	72,115	75,017	12,986	-	-	5,373	-	3,736
Temporary Equity Redeemable Noncontrolling Interests	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Total Assets	267,632	277,976	226,527	251,211	263,494	288,046	161,399	70,784	71,902	84,999	96,812	98,297	160,416	217,239	253,183	275,566	176,176	201,819	220,622	243,509	261,391	176,808	166,210	176,085	86,071	96,092	87,270	94,076	42,087	12,223	-	17,377	-	14,207
Total Current Assets	248,062	259,354	190,881	205,032	205,782	241,261	134,501	57,493	57,997	70,955	82,714	83,803	145,370	137,894	156,813	179,499	145,519	171,172	192,256	200,221	234,122	175,751	157,349	138,556	85,590	95,638	86,833	86,524	39,360	10,444	-	16,334	-	-
Total Current Liabilities	19,789	16,217	16,726	22,931	17,839	14,916	14,505	14,874	12,788	17,745	20,603	22,432	38,989	42,748	36,228	27,342	22,280	20,069	13,823	12,762	9,993	8,369	5,637	6,223	4,591	5,507	3,729	1,555	1,897	1,424	-	1,451	-	367
Total Liab	47,794	42,224	46,328	53,870	46,913	54,231	49,105	33,134	31,145	35,633	38,637	28,385	75,141	80,009	70,930	60,442	29,848	27,616	20,150	18,247	17,132	8,664	5,921	6,595	4,949	5,852	4,059	1,555	80,205	1,427	-	38,132	-	370
Total Permanent Equity	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Total Stockholder Equity	219,838	235,752	180,199	197,341	216,581	233,815	112,294	37,650	40,757	49,366	58,175	69,912	85,275	137,230	182,253	215,124	146,328	174,203	200,472	225,262	244,259	168,144	160,289	169,490	81,122	90,240	83,211	92,521	-38,118	10,796	-	-20,755	-	13,837
Treasury Stock	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Warrants	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	78,305	-	-	-	-	-

Cash Flow

Currency in USD. All numbers in thousands.

	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Begin Period Cash Flow	22,063	35,937	57,019	20,202	30,171	9,851	10,757	9,588	19,043
Capital Expenditures	308	453	1,613	1,356	1,235	232	507	417	0
Cash And Cash Equivalents Changes	5,286	-13,874	-21,082	36,817	-9,969	20,320	-906	-	-
Cash Flows Other Operating	-5,617	1,689	778	-757	-4,306	-8	-1,269	-	-
Change In Cash	5,286	-13,874	-21,082	36,817	-9,969	20,320	-906	1,169	-9,455
Change In Working Capital	-1,343	-2,360	-2,703	9,438	865	4,252	-1,071	841	302
Change Receivables	149	4,898	-809	-4,380	-	-	-	-	-
Change To Account Receivables	149	4,898	-809	-4,380	-4,380	-4,380	-4,380	-	-
Change To Inventory	-	-	605	102	102	102	102	-	-
Change To Liabilities	4,125	-8,947	-5,127	13,756	4,564	1,810	-359	993	295
Change To Netincome	39,151	13,418	63,053	21,327	12,593	9,104	1,180	27	-
Change To Operating Activities	-5,147	-2,039	661	6,752	-3,699	2,442	-717	23	-
Depreciation	923	1,324	6,409	1,879	402	120	90	12	11
Dividends Paid	-	-	-	-	0	0	0	-	-
End Period Cash Flow	27,349	22,063	35,937	57,019	20,202	30,171	9,851	10,757	9,588
Free Cash Flow	-52,442	-39,086	-98,058	-102,167	-55,898	-34,835	-20,876	-8,053	-4,920
Investments	-167,324	6,840	73,106	77,845	-55,692	-61,903	-76,444	-1,362	-
Issuance Of Capital Stock	238,200	7,737	0	100,205	-	-	-	-	-
Net Borrowings	-11,483	10,913	-30,000	29,262	-78	-78	-78	-78	-
Net Income	-90,865	-51,015	-161,354	-132,738	-68,523	-48,079	-20,563	-8,517	-5,236
Other Cashflows From Financing Activities	-1,665	10,772	207	28,704	235	121	39,864	10,584	-4,535
Other Cashflows From Investing Activities	-	-	34,186	-67,122	34,186	34,186	-76,444	-	-
Other Non Cash Items	25,091	2,393	45,026	555	-54,261	3,000	284	1	3
Sale Purchase Of Stock	239,659	7,596	207	100,782	100,464	116,826	96,414	63,250	-
Total Cash From Financing Activities	225,052	18,372	-30,316	128,261	100,386	116,826	96,414	10,584	-
Total Cash From Operating Activities	-52,134	-38,633	-96,445	-100,811	-54,663	-34,603	-20,369	-7,636	-4,920
Total Cashflows From Investing Activities	-167,632	6,387	105,679	9,367	-55,692	-61,903	-76,951	-1,779	-

	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2013-12-31
Begin Period Cash Flow	68,264	36,342	27,349	53,602	113,447	35,267	22,063	25,396	32,587	53,992	35,937	29,898	31,654	34,197	57,019	26,590	46,035	54,881	20,202	60,055	32,708	23,677	30,171	17,796	31,815	13,131	9,851	25,419	9,853	8,469	10,757	18,888	9,345	-
Capital Expenditures	150	186	164	252	56	52	52	8	304	17	124	266	822	241	284	146	560	352	298	577	270	193	195	62	64	66	40	132	133	165	77	269	16	0
Cash And Cash Equivalents Changes	-	31,922	8,993	-26,253	-59,845	78,180	13,204	-3,333	-7,191	-21,405	18,055	-	-1,756	-2,543	-22,822	30,429	-19,445	-8,846	34,679	-	27,347	9,031	-6,494	-	-14,019	18,684	3,280	-	-	-	-	-	-	-
Cash Flows Other Operating	-	1,121	188	-5,609	5,215	-2,973	-2,250	386	413	552	338	-	1,305	119	1,854	2,704	-5,806	1,323	1,022	-	-434	-1,300	-2,597	-	80	-41	71	-	-	-	-	-	-	-
Change In Cash	-6,611	31,922	8,993	-26,253	-59,845	78,180	13,204	-3,333	-7,191	-21,405	18,055	6,039	-1,756	-2,543	-22,822	30,429	-19,445	-8,846	34,679	-39,853	27,347	9,031	-6,494	12,375	-14,019	18,684	3,280	-15,568	15,566	1,384	-2,288	-8,131	9,543	-
Change In Working Capital	7,754	368	-3,534	-519	4,995	-2,939	-2,880	2,443	-4,649	-3,139	2,985	-3,447	-630	2,215	-841	5,700	-2,209	3,821	2,126	2,080	689	1,399	-3,303	1,237	-861	1,758	2,118	-389	-126	-331	-225	-187	1,062	-
Change Receivables	-	-4	-10	188	128	-122	-45	115	-112	158	4,737	-	1,506	-3,553	-10,956	-3,828	1,149	-1,701	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change To Account Receivables	40	-4	-10	188	128	-122	-45	115	-112	158	4,737	12,194	1,506	-3,553	-10,956	-3,828	1,149	-1,701	-1,701	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Change To Inventory	-	-	-	-	-	-	-	-	-	-	-	3	-4	671	-65	1,146	-18	-1,026	-1,026	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Change To Liabilities	-	-749	-3,712	4,902	-348	-3,132	-585	1,942	-4,950	-3,849	-2,090	-6,210	-3,437	4,978	8,326	4,961	2,466	5,225	1,104	5,171	1,123	2,699	-706	4,260	-941	1,799	2,047	198	82	-	-	993	-	295
Change To Netincome	-	292	1,146	6,051	5,354	8,632	19,114	2,322	2,567	3,309	5,220	1,029	30,958	24,052	4,862	5,362	4,707	5,249	6,009	12,593	3,673	3,304	3,153	9,104	1,618	1,354	4,006	1,180	-	-	-	27	-	-
Change To Operating Activities	-	2,790	-1,659	-3,069	2,284	315	-4,677	2,099	-5,115	-1,588	2,565	-9,434	-9,434	5,483	10,377	7,350	-4,579	2,171	1,810	-3,699	720	-931	-2,597	2,442	80	-41	-	-717	-	-	-	23	-	-
Depreciation	193	206	208	197	191	247	288	-449	591	606	576	320	1,632	2,231	2,226	958	384	315	222	181	116	55	50	40	32	27	21	33	32	22	3	3	3	-
Dividends Paid	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
End Period Cash Flow	61,653	68,264	36,342	27,349	53,602	113,447	35,267	22,063	25,396	32,587	53,992	35,937	29,898	31,654	34,197	57,019	26,590	46,035	54,881	20,202	60,055	32,708	23,677	30,171	17,796	31,815	13,131	9,851	25,419	9,853	8,469	10,757	18,888	9,345
Free Cash Flow	-7,967	-19,852	-21,133	-17,275	-10,662	-12,273	-12,232	-8,865	-12,454	-10,838	-6,929	-20,656	-24,181	-21,619	-31,602	-27,394	-30,418	-22,185	-22,170	-18,787	-13,984	-10,273	-12,854	-8,134	-9,969	-9,798	-6,934	-4,269	-10,701	-3,027	-2,879	-3,031	-1,602	-
Investments	-	-21,037	30,096	-8,976	-37,616	-45,418	-75,314	-2,297	5,541	-10,470	14,066	56,438	22,495	19,193	8,900	-3,238	10,954	13,638	56,491	-44,810	-29,940	-33	6,151	-61,671	-4,063	9,934	10,214	-76,444	-	-	-	-1,362	-	-
Issuance Of Capital Stock	-	72,744	0	0	0	134,852	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Borrowings	-	-	-	-	-11,483	-11,483	-11,483	-9	-36	-37	10,950	-30,131	-30,131	-120	-120	29,761	-164	-299	-36	-78	-78	-78	-78	-78	-	-	-	-78	-	-	-	-78	-	-
Net Income	-19,952	-20,532	-18,789	-22,804	-21,146	-18,161	-28,754	-13,173	-10,659	-11,597	-15,586	-18,594	-55,319	-49,876	-37,565	-38,551	-32,740	-31,218	-30,229	-22,934	-18,192	-14,838	-12,559	-11,475	-10,694	-12,871	-13,039	-4,714	-10,633	-2,594	-2,623	-2,597	-2,657	-
Other Cashflows From Financing Activities	72,733	67	30	-2	-84	1,019	-2,598	7,838	-242	-62	10,950	122	82	3	8,616	28,127	183	13,286	394	-78	-39,857	19,337	209	107	13	18,548	10,174	58,057	39,864	-664	-231	-4	10,588	-
Other Cashflows From Investing Activities	-	-	-	-	-	-	-	-	-	-	14,066	34,186	34,186	34,186	8,900	-67,122	0	0	0	0	-9,647	0	0	0	0	0	0	0	-	-	-	-	-	-
Other Non Cash Items	-	-3,400	-1,200	2,200	1,652	4,800	16,439	-182	626	0	1,767	-1,850	27,638	19,238	-311	-311	-	-	866	-1,837	-	-	-	216	-	-	2,784	285	1	-1	-	-	-	-
Sale Purchase Of Stock	-	72,827	37	-	-	135,895	103,764	7,838	-267	-	25	207	82	3	-	100,205	183	0	394	0	100,229	26	209	98,158	0	18,547	0	0	-612	-	-	63,250	-	-
Total Cash From Financing Activities	-11	72,811	30	-2	-11,567	135,871	100,750	7,829	-278	-97	10,918	-30,009	-70	-117	-120	128,183	19	-299	358	-78	80,918	19,337	209	98,265	13	18,548	58,057	58,057	39,252	-664	-231	-4	10,588	-
Total Cash From Operating Activities	-7,817	-19,666	-20,969	-17,075	-10,606	-12,221	-12,232	-8,857	-12,150	-10,821	-6,805	-20,390	-23,359	-21,378	-31,318	-27,248	-29,858	-21,833	-21,872	-18,210	-13,714	-10,080	-12,659	-8,072	-9,905	-9,732	-6,894	-4,137	-10,568	-2,862	-2,802	-2,762	-1,586	-
Total Cashflows From Investing Activities	-	-21,223	29,932	-9,176	-37,672	-45,470	-75,314	-2,305	5,237	-10,487	13,942	56,438	21,673	18,952	8,616	-70,506	10,394	13,286	56,193	-55,692	-39,857	-226	5,956	-61,903	-4,127	9,868	10,174	-76,951	-	5,655	-	-1,779	-	-

Income Statement

Currency in USD. All numbers in thousands.

	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Cost Of Revenue	4,713	5,133	4,055	6,850	1,207	0	0	0	-
Depreciation And Amortization	923	1,324	6,409	1,879	402	120	90	12	11
Discontinued Operations	-	139	-47,812	-50,634	-18,062	-18,062	-	-	-
Ebit	-90,865	-51,197	-161,354	-132,738	-70,353	-48,567	-20,667	-8,533	-5,257
Ebitda	-89,942	-49,873	-154,945	-130,859	-69,951	-48,447	-20,577	-8,521	-5,246
Extraordinary Items	-	-	-47,812	-50,634	1,837	-	-	-	-
Gross Profit	2,048	1,349	172	3,241	476	0	0	0	-
Income Before Tax	-90,865	-51,336	-113,542	-132,738	-70,353	-48,079	-20,563	-8,517	-5,236
Income Tax Expense	-	-182	-	0	-1,830	0	0	0	-
Interest Expense	0	0	0	0	0	0	0	0	0
Interest Income	-	-	-	-	-	-	104	-	-
Net Income	-90,865	-51,015	-161,354	-132,738	-68,523	-48,079	-20,563	-8,517	-5,236
Net Income Applicable To Common Shares	-90,865	-51,015	-161,354	-132,738	-68,523	-48,079	-23,129	-10,571	-
Net Income From Continuing Ops	-90,865	-51,154	-113,542	-132,738	-68,523	-48,079	-20,563	-8,517	-
Non Operating Income Net Other	-1,142	-424	-2,484	2,676	2,070	488	104	-	-
Non Recurring	-	-	18,504	-	-	-	-	-	-
Operating Income	-89,723	-50,912	-111,058	-135,414	-72,423	-48,567	-20,667	-8,533	-5,257
Other Operating Expenses	72,145	57,394	96,781	144,005	74,106	48,567	20,667	8,533	5,257
Preferred Stock And Other Adjustments	-	-	-	-	-	-	2,566	-	-
Reconciled Depreciation	923	1,324	6,409	1,879	402	-	-	-	-
Research Development	43,813	31,731	64,899	63,009	39,790	33,476	15,339	6,507	3,488
Selling And Marketing Expenses	-	283	671	47,997	-	-	-	-	-
Selling General Administrative	23,619	20,530	27,156	26,149	33,109	15,091	5,328	2,026	1,769
Tax Provision	0	-182	0	0	-1,830	-	-	-	-
Total Operating Expenses	67,432	52,261	92,726	137,155	72,899	48,567	20,667	8,533	5,257
Total Other Income Expense Net	-1,142	-424	-2,484	2,676	2,070	488	104	16	21
Total Revenue	6,761	6,482	4,227	10,091	1,683	0	0	0	-

	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2013-12-31
Cost Of Revenue	923	1,068	1,155	1,149	1,099	1,263	1,202	1,286	1,189	1,389	1,269	1,027	826	2,703	2,777	3,509	1,193	1,181	967	754	453	15,040	12,880	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation And Amortization	193	206	208	197	191	247	288	-449	591	606	576	320	1,632	2,231	2,226	958	384	315	222	181	116	55	50	40	32	27	21	33	32	22	3	3	3	-	-
Discontinued Operations	-	-	-	-	-	-	-	424	424	-27	-258	854	-32,181	-32,181	-32,181	-32,181	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ebit	-20,874	-20,532	-18,789	-22,804	-21,146	-18,161	-28,754	-13,355	-10,659	-11,597	-15,586	-18,594	-55,319	-49,876	-37,565	-38,551	-32,740	-31,218	-30,229	-24,764	-18,192	-15,295	-12,930	-11,627	-10,812	-12,989	-13,139	-4,802	-10,640	-2,596	-2,629	-2,602	-2,662	0	0
Ebitda	-20,681	-20,326	-18,581	-22,607	-20,955	-17,914	-28,466	-13,804	-10,068	-10,991	-15,010	-18,274	-53,687	-47,645	-35,339	-37,593	-32,356	-30,903	-30,007	-24,583	-18,076	-15,240	-12,880	-11,587	-10,780	-12,962	-13,118	-4,769	-10,608	-2,574	-2,626	-2,599	-2,659	-	-
Effect Of Accounting Charges	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Extraordinary Items	-	-	-	-	-	-	-	-	-	-	-258	854	-32,181	-16,485	-10,284	-14,994	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Gross Profit	18,095	460	298	352	560	561	575	294	260	657	138	68	157	3,162	2,264	160	435	2,495	151	245	231	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-19,952	-20,532	-18,789	-22,804	-21,146	-18,161	-28,754	-13,779	-10,659	-11,570	-15,328	-19,448	-23,138	-49,876	-37,565	-38,551	-32,740	-31,218	-30,229	-24,764	-18,192	-14,838	-12,559	-11,475	-10,694	-12,871	-13,039	-4,714	-10,633	-2,594	-2,623	-2,597	-2,657	0	0
Income Tax Expense	-	-	-	-	-	-	-	-182	-	-	-	-	-	-	-	0	0	0	-1,830	-1,830	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	7	0	0	0	0	0	0
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	-19,952	-20,532	-18,789	-22,804	-21,146	-18,161	-28,754	-13,173	-10,659	-11,597	-15,586	-18,594	-55,319	-49,876	-37,565	-38,551	-32,740	-31,218	-30,229	-22,934	-18,192	-14,838	-12,559	-11,475	-10,694	-12,871	-13,039	-4,714	-10,633	-2,594	-2,623	-2,597	-2,657	0	0
Net Income Applicable To Common Shares	-	-20,532	-18,789	-22,804	-21,146	-18,161	-28,754	-13,173	-10,659	-11,597	-15,586	-18,594	-55,319	-49,876	-37,565	-38,551	-32,740	-31,218	-30,229	-34,329	-18,192	-14,838	-12,559	-88,869	-10,694	-12,871	-13,039	-23,129	-11,628	0	0	-10,571	0	0	0
Net Income From Continuing Ops	-	-20,532	-18,789	-22,804	-21,146	-18,161	-28,754	-13,597	-10,659	-11,570	-15,328	-19,448	-23,138	-49,876	-37,565	-38,551	-32,740	-31,218	-30,229	-34,329	-18,192	-14,838	-12,559	-88,869	-10,694	-12,871	-13,039	-20,563	-10,633	0	0	-8,517	0	0	0
Non Operating Income Net Other	-	462	118	89	-851	-155	-225	-219	-194	-189	178	-	-	-	-230	-	710	760	719	-	564	457	371	-	118	118	100	-	-	-	-	-	-	-	-
Non Recurring	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Operating Income	-20,874	-20,994	-18,907	-22,893	-20,295	-18,006	-28,529	-13,560	-10,465	-11,381	-15,506	-17,553	-22,864	-49,791	-37,335	-39,038	-33,450	-31,978	-30,948	-25,442	-18,756	-15,295	-12,930	-11,627	-10,812	-12,989	-13,139	-4,802	-10,640	-2,596	-2,629	-2,602	-2,662	0	0
Other Items	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Operating Expenses	39,892	25,922	21,560	22,194	21,054	15,030	13,867	15,140	11,914	13,427	16,913	19,200	23,295	37,152	42,376	42,707	35,078	34,154	32,066	26,441	19,440	15,295	12,930	11,627	10,812	12,989	13,139	4,802	10,640	2,596	2,629	2,602	2,662	0	0
Preferred Stock And Other Adjustments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	995	-	-	-	-	-	-
Reconciled Depreciation	-	206	208	197	191	247	288	-449	591	606	576	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research Development	23,656	18,779	14,306	14,102	13,976	7,897	7,838	8,956	6,866	6,466	9,444	11,565	16,183	17,622	19,919	19,537	15,931	13,984	13,606	13,189	10,864	7,965	7,772	6,943	7,162	9,836	9,535	2,402	9,408	1,793	1,737	2,054	2,097	2,356	3,488
Selling And Marketing Expenses	-	-	-	-	-	-	-	283	-	-	-	42	112	7,177	9,828	12,967	11,380	12,368	11,233	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Selling General Administrative	5,813	6,075	6,099	6,943	5,979	5,870	4,827	4,898	3,859	5,572	6,200	6,566	6,174	7,990	8,193	6,694	6,574	6,621	6,260	12,498	8,123	7,330	5,158	4,684	3,650	3,153	3,604	2,400	1,232	803	892	548	565	3,263	5,246
Tax Provision	-	-	-	0	-	-	-	-182	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Operating Expenses	38,969	24,854	20,405	21,045	19,955	13,767	12,665	13,854	10,725	12,038	15,644	18,173	22,469	34,449	39,599	39,198	33,885	32,973	31,099	25,687	18,987	15,295	12,930	11,627	10,812	12,989	13,139	4,802	10,640	2,596	2,629	2,602	2,662	0	0
Total Other Income Expense Net	922	462	118	89	-851	-155	-225	-219	-194	-189	178	-1,895	-274	-85	-230	487	710	760	719	678	564	457	371	152	118	118	100	88	7	2	6	5	5	0	0
Total Revenue	19,018	1,528	1,453	1,501	1,659	1,824	1,777	1,580	1,449	2,046	1,407	1,095	983	5,865	5,041	3,669	1,628	3,676	1,118	999	684	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue	6,761
Cost of Revenue	-4,713
Gross Profit	2,048	2,048

Operating Income (+$)
Gross Profit	2,048
Operating Expense	-67,432
Operating Income	-89,723	-65,384

Operating Expense (+$)
Research Development	43,813
Selling General Administrative	23,619
Selling And Marketing Expenses	-
Operating Expense	67,432	67,432

Net Interest Income (+$)
Interest Income	-
Interest Expense	-0
Net Interest Income	-	0

Pretax Income (+$)
Operating Income	-89,723
Net Interest Income	-
Other Non-Operating Income Expenses	-1,142
Income Before Tax (EBT)	-90,865	-88,581 EBIT - interestExpense = -90,865 -90,865 -90,865
Interest Expense	0
Earnings Before Interest and Taxes (ebit)	-90,865	-90,865
Earnings Before Interest and Taxes (ebitda)	-89,942

After tax Income (+$)
Income Before Tax	-90,865
Tax Provision	-0
Net Income From Continuing Ops	-90,865	-90,865
Net Income	-90,865
Net Income Applicable To Common Shares	-90,865

Non-recurring Events
Discontinued Operations	-
Extraordinary Items	-
Effect of Accounting Charges	-
Other Items	-
Non Recurring	-
Other Operating Expenses	72,145
Total Other Income/Expenses Net	-1,142	1,142